Literature DB >> 28343015

Systemic delivery of the tumor necrosis factor gene to tumors by a novel dual DNA-nanocomplex in a nanoparticle system.

Vasundhara Shukla1, Manu Dalela1, Manika Vij2, Ralph Weichselbaum3, Surender Kharbanda4, Munia Ganguli2, Donald Kufe5, Harpal Singh6.   

Abstract

Many cancers fail to respond to immunotherapy as a result of immune suppression by the tumor microenvironment. The exogenous expression of immune cytokines to reprogram the tumor microenvironment represents an approach to circumvent this suppression. The present studies describe the development of a novel dual nanoparticle (DNP) system for driving DNA expression vectors encoding inflammatory cytokines in tumor cells. The DNP system consists of a DNA expression vector-cationic peptide nanocomplex (NC) surrounded by a diblock polymeric NP. Tumor necrosis factor alpha (TNF) was selected as the prototype cytokine for this system, based on its pleotropic inflammatory and anti-cancer activities. Our results demonstrate that the DNP system is highly effective in driving expression of TNF in tumor cells. We also demonstrate that the DNPs are effective in inducing apoptosis and anti-tumor activity. These findings support a novel immunotherapeutic approach for the intratumoral delivery of DNA vectors that express inflammatory cytokines.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  DNA expression vector; Intratumoral delivery; Nanocomplexes; Nanoparticles; Tumor necrosis factor

Mesh:

Substances:

Year:  2017        PMID: 28343015      PMCID: PMC5706451          DOI: 10.1016/j.nano.2017.03.004

Source DB:  PubMed          Journal:  Nanomedicine        ISSN: 1549-9634            Impact factor:   5.307


  24 in total

Review 1.  Non-viral vectors for gene-based therapy.

Authors:  Hao Yin; Rosemary L Kanasty; Ahmed A Eltoukhy; Arturo J Vegas; J Robert Dorkin; Daniel G Anderson
Journal:  Nat Rev Genet       Date:  2014-07-15       Impact factor: 53.242

Review 2.  Immune checkpoint blockade: a common denominator approach to cancer therapy.

Authors:  Suzanne L Topalian; Charles G Drake; Drew M Pardoll
Journal:  Cancer Cell       Date:  2015-04-06       Impact factor: 31.743

3.  Controlling DNA-nanoparticle serum interactions.

Authors:  Kyryl Zagorovsky; Leo Y T Chou; Warren C W Chan
Journal:  Proc Natl Acad Sci U S A       Date:  2016-11-16       Impact factor: 11.205

4.  Tumor-targeted gene delivery: an attractive strategy to use highly active effector molecules in cancer treatment.

Authors:  R Kircheis; L Wightman; M Kursa; E Ostermann; E Wagner
Journal:  Gene Ther       Date:  2002-06       Impact factor: 5.250

5.  Intracellular Targeting of the Oncogenic MUC1-C Protein with a Novel GO-203 Nanoparticle Formulation.

Authors:  Masanori Hasegawa; Raj Kumar Sinha; Manoj Kumar; Maroof Alam; Li Yin; Deepak Raina; Akriti Kharbanda; Govind Panchamoorthy; Dikshi Gupta; Harpal Singh; Surender Kharbanda; Donald Kufe
Journal:  Clin Cancer Res       Date:  2015-02-23       Impact factor: 12.531

6.  An injectable nanoparticle generator enhances delivery of cancer therapeutics.

Authors:  Rong Xu; Guodong Zhang; Junhua Mai; Xiaoyong Deng; Victor Segura-Ibarra; Suhong Wu; Jianliang Shen; Haoran Liu; Zhenhua Hu; Lingxiao Chen; Yi Huang; Eugene Koay; Yu Huang; Jun Liu; Joe E Ensor; Elvin Blanco; Xuewu Liu; Mauro Ferrari; Haifa Shen
Journal:  Nat Biotechnol       Date:  2016-03-14       Impact factor: 54.908

7.  Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results.

Authors:  Joseph M Herman; Aaron T Wild; Hao Wang; Phuoc T Tran; Kenneth J Chang; Gretchen E Taylor; Ross C Donehower; Timothy M Pawlik; Mark A Ziegler; Hongyan Cai; Dionne T Savage; Marcia I Canto; Jason Klapman; Tony Reid; Raj J Shah; Sarah E Hoffe; Alexander Rosemurgy; Christopher L Wolfgang; Daniel A Laheru
Journal:  J Clin Oncol       Date:  2013-01-22       Impact factor: 44.544

8.  Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study.

Authors:  D R Spriggs; M L Sherman; H Michie; K A Arthur; K Imamura; D Wilmore; E Frei; D W Kufe
Journal:  J Natl Cancer Inst       Date:  1988-09-07       Impact factor: 13.506

Review 9.  Gene therapy for cancer: present status and future perspective.

Authors:  Magid H Amer
Journal:  Mol Cell Ther       Date:  2014-09-10

Review 10.  Gene therapy: progress and predictions.

Authors:  Mary Collins; Adrian Thrasher
Journal:  Proc Biol Sci       Date:  2015-12-22       Impact factor: 5.349

View more
  2 in total

Review 1.  Inflammatory and Anti-Inflammatory Equilibrium, Proliferative and Antiproliferative Balance: The Role of Cytokines in Multiple Myeloma.

Authors:  Caterina Musolino; Alessandro Allegra; Vanessa Innao; Andrea Gaetano Allegra; Giovanni Pioggia; Sebastiano Gangemi
Journal:  Mediators Inflamm       Date:  2017-09-26       Impact factor: 4.711

Review 2.  Poly(Ethylene Glycol)-Polylactide Micelles for Cancer Therapy.

Authors:  Jixue Wang; Shengxian Li; Yuping Han; Jingjing Guan; Shirley Chung; Chunxi Wang; Di Li
Journal:  Front Pharmacol       Date:  2018-03-08       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.